Arvinas logo
Arvinas
ARVN | NASDAQ
Chart Builder DCF Calculator
$6.77
-$0.05 (-0.73%)
At close: Nov 16, 2026, 4:00 PM ET
$6.77
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:43 PM ET

Arvinas Company Profile

Company profile explained

Company Profile

Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.

Key Executives

Name Position
Randy Teel CEO, President & Director
Andrew Saik Chief Financial Officer & Treasurer
Angela Cacace Chief Scientific Officer
David Loomis Vice President & Chief Accounting Officer
Jared Freedberg General Counsel & Corporate Secretary
Jeff Boyle Vice President of Investor Relations
Kelly Page Senior Vice President & Global Head of Oncology Strategy and Program Leadership
Paul McInulty Senior Vice President of Regulatory Affairs
Steve Weiss Senior Vice President & Chief Human Resources Officer

Latest SEC Filings

Date Type Title
Sep 28, 2026 S-8 Filing
Aug 31, 2026 S-8 Filing
Aug 14, 2026 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Aug 04, 2026 10-Q Quarterly Report
Aug 04, 2026 8-K Current Report
Jun 26, 2026 4 Filing
Jun 26, 2026 4 Filing
Jun 26, 2026 4 Filing
Jun 26, 2026 4 Filing
Jun 26, 2026 4 Filing
View All SEC Filings ➞
Arvinas
Arvinas logo
Country United States
IPO Date Sep 27, 2018
Industry Biotechnology
Sector Healthcare
Employees 246
CEO Randy Teel

Contact Details

5 Science Park New Haven, Connecticut 06511 United States

Stock Details

Ticker Symbol ARVN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001655759
CUSIP Number 04335A105
ISIN Number US04335A1051
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.